With pharma interest in rare-disease drugs becoming quite common, Protalix BioTherapeutics, maker of a rare disease drug partnered with Pfizer ($PFE), said today that it has hired Citigroup to help review "a broad array of product partnering, technology sharing and other strategic alternatives" for the Israel-based biotech company.
Stock for Pfizer's animal health spinoff Zoetis soared 21% after raising more than $2.2 billion in its initial public offering.
Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant ( email | Twitter ) and we will feature it...
The spinoff of Pfizer's animal health unit has gone off with such success that it may make some wonder why CEO Ian Read didn't keep it and dump the challenging pharmaceutical business.
German drugmaker Boehringer Ingelheim has bolstered its efforts in the respiratory disease arena with a new mobile app that healthcare pros can tap during exams on patients with smoker's cough.
Pfizer's animal health group Zoetis goes public today, with an IPO valued at up to $2.2 billion.
Analysts expect the U.S. vaccine market to rack up to $12.8 billion in sales for 2012. And Transparency Market Research says the industry can expect to see 5.3% growth through 2018. But low vaccination rates among U.S. adults may hamper that upward trend.
The news that Merck KGaA was planning to shutter the gleaming Merck Serono facility in Geneva hit hard last year, spurring protests and appeals that went unheeded at the German pharma company.
Pfizer ($PFE) may, in fact, split itself in two, CEO Ian Read says. But don't hold your breath for the securities filings. The company would have to make a lot of structural changes before a legal separation is even possible.
The FDA will now allow use of Prevnar 13 in children and adolescents ages 6 to 17, a recent expansion that could allow Pfizer to hit lofty sales goals.